Kronos Bio Inc
NASDAQ:KRON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Toll Brothers Inc
NYSE:TOL
|
US |
|
S
|
Saint Bella Inc
HKEX:2508
|
CN |
|
T
|
Toyota Motor Corp
DUS:TOM
|
JP |
|
T
|
TAC Consumer PCL
SET:TACC
|
TH |
|
Fuchun Technology Co Ltd
SZSE:300299
|
CN |
|
Sinomine Resource Group Co Ltd
SZSE:002738
|
CN |
|
Nfon AG
XETRA:NFN
|
DE |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Kronos Bio Inc
NASDAQ:KRON
|
53.7m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.4B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.6B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Kronos Bio Inc
Glance View
Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. The company is headquartered in San Mateo, California and currently employs 96 full-time employees. The company went IPO on 2020-10-09. The firm is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Kronos Bio Inc is -701.5%, which is above its 3-year median of -2 662.6%.
Over the last 2 years, Kronos Bio Inc’s Net Margin has increased from -10 096.7% to -701.5%. During this period, it reached a low of -10 096.7% on Mar 31, 2023 and a high of -701.5% on May 1, 2025.
